Dermatologic and Ophthalmic Drugs Advisory Committee; Cancellation

---
identifier: "/us/fr/2010-15352"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Dermatologic and Ophthalmic Drugs Advisory Committee; Cancellation"
title_number: 0
title_name: "Federal Register"
section_number: "2010-15352"
section_name: "Dermatologic and Ophthalmic Drugs Advisory Committee; Cancellation"
positive_law: false
currency: "2010-06-24"
last_updated: "2010-06-24"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2010-15352"
document_type: "notice"
publication_date: "2010-06-24"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "75 FR 36101"
fr_volume: 75
docket_ids:
  - "Docket No. FDA-2010-N-0001"
fr_action: "Notice."
---


#  Dermatologic and Ophthalmic Drugs Advisory Committee; Cancellation

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for June 28, 2010, is cancelled. This meeting was announced in the *Federal Register* of May 11, 2010 (75 FR 26264). The meeting was to discuss new drug application (NDA) 22-340, voclosporin 10-milligram capsules, by Lux Biosciences Inc. This meeting has been cancelled to allow time for the resolution of several outstanding issues. The agency intends to continue evaluating NDA 22-340 and, as needed, may schedule an advisory committee meeting in the future.

**FOR FURTHER INFORMATION CONTACT:**

Yvette Waples, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, e-mail: *[email protected]* , or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512534. Please call the Information Line for up-to-date information on this meeting.

Dated: June 18, 2010.

Thinh Nguyen,

Acting Associate Commissioner for Special Medical Programs.